Persistent Diarrhea and Eosinophilic Esophagitis Resulting From Chronic Cannabidiol Usage for Refractory Epilepsy
Authors:
Open Access
- 30 September 2022
- journal article
- case report
- Published by Wiley in JPGN Reports
- Vol. 3 (4) , e253
Abstract
Cannabidiol is used in the care of treatment‐resistant epilepsy. It has been associated with varying side effects, ranging from somnolence to diarrhea and weight loss. We present a patient on chronic cannabidiol therapy who had persistent diarrhea, abdominal pain, weight loss, and esophageal eosinophilia that improved with cannabidiol dose adjustment.Keywords
This publication has 8 references indexed in Scilit:
- A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure MedicationCNS Drugs, 2022
- Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsyEpilepsy & Behavior, 2021
- Nabilone administration in refractory chronic diarrhea: a case seriesBMC Gastroenterology, 2019
- Cannabinoid therapy in epilepsyCurrent Opinion in Neurology, 2019
- Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromesEpilepsy & Behavior, 2018
- Gut microbiome interactions with drug metabolism, efficacy, and toxicityTranslational Research, 2017
- Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trialThe Lancet Neurology, 2016
- Signaling in TRPV1-induced platelet activating factor (PAF) in human esophageal epithelial cellsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2010